[an error occurred while processing this directive] | [an error occurred while processing this directive]
Concurrent chemoradiotherapy with nimotuzumab and capecitabine for patients with unresectable, postoperative residual, or recurrent gastric cancer:a prospective study
Department of Radiation Oncology (Lu NN,Jin J,Ren H,Tang Y,Wang X,Li N,Feng YR,Wang SHL,网WH,Song YW,Liu YP,Fang H,Zhang JJ,Li SH,Li YX),Department of Diagnostic Radiology (Jiang LM),National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China
AbstractObjective To investigate the adverse effects and short-term therapeutic effect of concurrent chemoradiotherapy with nimotuzumab and capecitabine for patients with unresectable, postoperative residual, or recurrent gastric cancer. Methods A prospective phase Ⅱ study was performed in patients with pathologically confirmed gastric cancer. Inclusion criteria were as follows:unresectable, postoperative residual, or recurrent gastric cancer in which lesions could be measured;lesions which could receive radiotherapy;expected survival time>3 months. All patients received intensity-modulated radiotherapy (54 Gy in 30 fractions for planned gross tumor volume, 45 Gy in 25 fractions for the prophylactic area in lymph nodes) and concurrent capecitabine (1 600 mg/m2 per day for 35 days) and nimotuzumab (200 mg once a week). Common Terminology Criteria for Adverse Events, version 3.0 and Response Evaluation Criteria in Solid Tumors were used to evaluate acute adverse effects and short-term therapeutic effect. ResultsA total of 30 patients were enrolled from 2010 to 2013. The median age was 57 years (range 35-66 years). There were 23 patients with postoperative residual or recurrent gastric cancer and 7 with unresectable gastric cancer. Twenty-eight patients received chemotherapy before being enrolled in this study and achieved stable disease or progression. During concurrent chemoradiotherapy, 5 patients (17%) experienced grade 3 acute adverse events, mainly thrombocytopenia (10%). At one month after treatment, the in-field objective response rate and stable disease rate were 43%(complete response 4%, partial response 39%) and 50%, respectively, and the systemic objective response rate and stable disease rate were 32% and 43%, respectively. Conclusions In patients with unresectable, postoperative residual, or recurrent gastric cancer, concurrent chemoradiotherapy with nimotuzumab and capecitabine has good safety, tolerability, short-term therapeutic effect, and in-field control. Clinical Trial Registry ClinicalTrials.gov, registration number:NCT01180166.
. Concurrent chemoradiotherapy with nimotuzumab and capecitabine for patients with unresectable, postoperative residual, or recurrent gastric cancer:a prospective study[J]. Chinese Journal of Radiation Oncology, 2016, 25(5): 457-461.
. Concurrent chemoradiotherapy with nimotuzumab and capecitabine for patients with unresectable, postoperative residual, or recurrent gastric cancer:a prospective study[J]. Chinese Journal of Radiation Oncology, 2016, 25(5): 457-461.
[1]Kamangar F,Dores GM,Anderson WF.Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world[J].J Clin Oncol,2006,24():2137-2150. [2]Chen W,Zheng R,Baade PD,et al. Cancer statistics in China,2015[J].CA Cancer J Clin 2016, [3]王鑫,金晶,李晔雄,等.局部晚期胃癌根治术后复发部位分析及对术后放疗意义的探讨[J].中华放射肿瘤学杂志 2011,20():133-137. [4]Yoo CH,Noh SH,Shin DW,et al. Recurrence following curative resection for gastric carcinoma[J].Br J Surg,2000,87:236-242. [5]Lim DH,Kim DY,Kang MK,et al. Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy:a radiation oncologist′s view[J].Br J Cancer,2004,91:11-17. [6]Yuan ST,Wang FL,Liu N,et al. Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence[J].Am J Clin Oncol,2015,38:130-134. [7]Hawkes E,Okines AF,Papamichael D,et al. Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer[J].Eur J Cancer,2011,47:1146-1151. [8]Terashima M,Kitada K,Ochiai A,et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage Ⅱ/Ⅲ gastric cancer[J].Clin Cancer Res,2012,18:5992-6000. [9]Jin T,Zhu Y,Luo JL,et al. Prospective phase Ⅱ trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer[J].Int J Colorec Dis,2015,30:337-345. [10]Solomon MT,Selva JC,Figueredo J,et al. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients:results from a randomized,double blind trial[J].BMC Cancer,2013,13:299. [11]Wang X,Jin J,Li YX,et al. Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer[J].World J Gastroenterol,2014,20:1067-1073. [12]Smalley SR,Gunderson L,Tepper J,et al. Gastric surgical adjuvant radiotherapy consensus report:rationale and treatment implementation[J].Int J Radiat Oncol Biol Phys,2002,52:283-293. [13]Park SH,Kim YS,Hong J,et al. Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer:a noncomparative phase Ⅱ study[J].Anticancer Drugs,2008,19:303-307. [14]Reed VK,Krishnan S,Mansfield PF,et al. Incidence,natural history,and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherap[J].Int J Radiat Oncol Biol Phys,2008,71:741-747. [15]Sun J,Sun YH,Zeng ZC,et al. Consideration of the role of radiotherapy for abdominal lymph node metastases in patients with recurrent gastric cancer[J].Int J Radiat Oncol Biol Phys,2010,77:384-391. [16]Iacovelli R,Pietrantonio F,Farcomeni A,et al. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies[J].PLoS One,2014,9:e108940. [17]Hironaka S,Ueda S,Yasui H,et al. Randomized,open-label,phase Ⅲ study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum:WJOG 4007 trial[J].J Clin Oncol,2013,31:4438-4444. [18]Shi L,Wu C,Wu J,et al. Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer[J].Radiat Oncol,2012,7:114. [19]Kim C,Lee JL,Ryu MH,et al. A prospective phase Ⅱ study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer[J].Invest New Drugs,2011,29:366-373. [20]Lordick F,Kang YK,Chung HC,et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND):a randomised,open-label phase 3 trial[J].Lancet Oncol,2013,14:490-499. [21]Waddell T,Chau I,Cunningham D,et al. Epirubicin,oxaliplatin,and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3):a randomised,open-label phase 3 trial[J].Lancet Oncol,2013,14:481-489. [22]van Cutsem E,Kohne CH,Hitre E,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J].N Engl J Med,2009,360:1408-1417. [23]Maughan TS,Adams RA,Smith CG,et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer:results of the randomised phase 3 MRC COIN trial[J].Lancet,2011,377:2103-2114.
2016, Vol. 25 
